Home > Insider Trading > Filing (0001179110-20-010711)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1479419	Kala Pharmaceuticals Inc.	KALA	Pharmaceutical Preparations (2834)	270604595

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1605767	Todd Bazemore	C/O Kala Pharmaceuticals, Inc. 490 Arsenal Way, Suite 120 Watertown MA 02472	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-10-26	81,000	$0.00	110,000	No	4	A	Direct
Common Stock	Acquisiton	2020-06-05	2	$13.39	2	No	4	P	Indirect	By son
Common Stock	Acquisiton	2020-10-22	40	$7.60	42	No	4	P	Indirect	By son

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	P	Indirect	By son
No	4	P	Indirect	By son

Footnotes

On June 25, 2020, the reporting person was granted performance-based restricted stock unit ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with the Issuer, the RSUs will vest as to 50% of the shares underlying the RSUs on October 26, 2021, the first anniversary of the achievement of the performance condition, and as to the remaining 50% of the shares underlying the RSUs on October 26, 2022, the second anniversary of the achievement of the performance condition.
Includes 100,000 unvested RSUs.
These transactions are being reported late because these shares were acquired by the reporting person's adult son without the reporting person's knowledge.
The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.